ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis—study protocol for an interventional randomised controlled trial
Dominic Crocombe(Royal Free London NHS Foundation Trust), Alastair O’Brien(The Royal Free Hospital), Louise China(Royal Free London NHS Foundation Trust), Nick Freemantle(MRC Clinical Trials Unit at UCL), Ewan Forrest(Glasgow Royal Infirmary), Gavin Wright(Basildon Hospital), J Portal(University Hospitals Bristol NHS Foundation Trust), David Peter Gear(Cancer Research UK), Indran Balakrishnan(Royal Free London NHS Foundation Trust), Ekaterina Bordea(MRC Clinical Trials Unit at UCL), Coral Hollywood(Gloucestershire Royal Hospital), Yiannis Kallis(Queen Mary University of London), Rachael Hunter(MRC Clinical Trials Unit at UCL), Paul Richardson(University of Liverpool), Lynsey Corless(University of Hull), Norin Ahmed(MRC Clinical Trials Unit at UCL), Stuart McPherson(Newcastle upon Tyne Hospitals NHS Foundation Trust), Tasheeka Jeyapalan(MRC Clinical Trials Unit at UCL), Victoria Danquah(MRC Clinical Trials Unit at UCL), Hakim‐Moulay Dehbi(MRC Clinical Trials Unit at UCL), Marisa Chau(MRC Clinical Trials Unit at UCL), Iulia Munteanu, Stephen Ryder(Nottingham University Hospitals NHS Trust), Amandeep Singh Virk(MRC Clinical Trials Unit at UCL), John Dillon(Mayo Clinic)
Cited by 18
Related Papers
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
|Nature Genetics|2009|1.1k
Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial
|The Lancet|2017|1k
MAIT cells are activated during human viral infections
|Nature Communications|2016|526